Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

New York mum Kait Handler, 40, has explained her reasons for giving her clinically obese 12-year-old Birdie semaglutide, ...

The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Approval announced for injection medication aimed at treatment for adults for obesity and risk of non-fatal myocardial ...

It's the diabetes turned 'weight loss' drug that's gone viral in just a few short years. Ozempic has been steeped in ...

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose weight. While these drugs are becoming wildly popular, they can cause ...

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...